Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT01428063) enrolled 227 people with hepatitis C across three treatment groups: 99 received daclatasvir plus asunaprevir; 122 received daclatasvir, asunaprevir, and two additional medicines (pegylated interferon and ribavirin); and 6 received daclatasvir with just the two additional medicines. The trial was measuring how many participants had undetectable levels of the hepatitis C virus in their blood at various points during and after treatment — including at 4 weeks, 12 weeks, and at the end of treatment. The main goal (the primary outcome) focused specifically on people with a genotype 1 strain of hepatitis C who had not responded to previous treatment. The reported data shows that for the primary outcome — participants in the daclatasvir plus asunaprevir plus interferon and ribavirin group who had previously not responded to treatment — 94.6% had undetectable virus levels at 12 weeks after finishing treatment (known as SVR12, meaning the virus was no longer detectable 12 weeks after the course ended). For the secondary outcomes, the reported SVR12 figures varied across different subgroups. For example, among those who had previously failed a different antiviral called asunaprevir, 100% reached SVR12, while among those who had previously failed daclatasvir, 40% did. Across other measures taken during treatment — such as how many people had undetectable virus at week 4 and week 12 of treatment — the reported figures generally ranged from around 64% to 100% depending on the group and the time point measured. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Hepatitis C Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must have previously taken part in a clinical trial involving one of these experimental drugs (BMS-790052, BMS-650032, or BMS-791325) and were in the control group, meaning you received the standard treatment (pegIFNα-2a/ribavirin) plus a placebo instead of the experimental drug
- You must have Hepatitis C virus (HCV) of genotype 1, 2, 3, or 4 — but not a mix of more than one genotype at the same time
- The Hepatitis C virus must still be detectable in your blood at the time of joining
Who may not be able to join:
- You cannot join if you left a previous BMS Hepatitis C trial early because of a bad reaction or side effect related to the standard treatment (pegIFNα-2a/ribavirin)
- You cannot join if you have received any other Hepatitis C treatment after your participation in the earlier BMS trial
- You cannot join if you test positive for Hepatitis B, HIV-1, or HIV-2 at the screening stage
- You cannot join if you have a liver condition caused by something other than Hepatitis C
- You cannot join if there is evidence that your liver disease has reached an advanced stage where the liver is no longer functioning properly (sometimes called decompensated cirrhosis), as shown by scans or a liver biopsy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
10 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12) for All Nonresponders With Genotype 1 Hepatitis C Virus (HCV)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.